Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPP100 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| SPP100 | DRUG | - |
| SPP100 (aliskiren) | DRUG | - |
Inclusion Criteria: * Diagnosed as essential hypertension - Exclusion Criteria: * Patients with secondary hypertension or suspected of having secondary hypertension. * Patients suspected of having malignant hypertension * Patients with any serious diseases or symptoms
SPP100 is an investigational small molecule being developed for the treatment of hypertension, also known as high blood pressure. It is currently in clinical development and has not been approved by regulatory authorities. The drug has been studied in patients with essential hypertension, including mild to moderate forms of the condition.
SPP100 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company has conducted clinical trials of SPP100 in patients with hypertension, with studies completed in Switzerland and Japan.
SPP100 is in Phase 2 clinical development for hypertension. The drug has completed two clinical trials, including a Phase 2 study and a Phase 1 study, with a total of 334 patients enrolled. SPP100 is still investigational and has not received FDA approval.
SPP100 has completed two clinical trials. The first, NCT00246584, was a Phase 2 long-term study in 300 patients with essential hypertension in Switzerland. The second, NCT00424541, was a Phase 1 pharmacokinetic and pharmacodynamic study in 34 Japanese patients with mild to moderate essential hypertension.
Yes, SPP100 is also known as aliskiren. The Phase 1 clinical trial NCT00424541 specifically studied the pharmacokinetic and pharmacodynamic profiles of aliskiren in Japanese patients with mild to moderate essential hypertension. This confirms that SPP100 and aliskiren refer to the same drug compound.